机译:PD-L1驱动的耐受性可保护Neurogenin3诱导的胰岛新生,以逆转NOD小鼠中已建立的1型糖尿病。
Division of Diabetes, Endocrinology and Metabolism, Diabetes and Endocrinology Research Center, and Department of Medicine, Baylor College of Medicine, Houston, TX;
Division of Diabetes, Endocrinology and Metabolism, Diabetes and Endocrinology Research Center, and Department of Medicine, Baylor College of Medicine, Houston, TX;
Division of Diabetes, Endocrinology and Metabolism, Diabetes and Endocrinology Research Center, and Department of Medicine, Baylor College of Medicine, Houston, TX;
Division of Diabetes, Endocrinology and Metabolism, Diabetes and Endocrinology Research Center, and Department of Medicine, Baylor College of Medicine, Houston, TX;
Division of Cardiology, Department of Pediatrics, University of Texas Medical School at Houston, Houston, TX;
Department of Cancer Biology, Cleveland Clinic, Lerner Research Institute, Cleveland, OH;
Department of Cancer Biology, Cleveland Clinic, Lerner Research Institute, Cleveland, OH;
Division of Diabetes, Endocrinology and Metabolism, Diabetes and Endocrinology Research Center, and Department of Medicine, Baylor College of Medicine, Houston, TX;
Division of Diabetes, Endocrinology and Metabolism, Diabetes and Endocrinology Research Center, and Department of Medicine, Baylor College of Medicine, Houston, TX;
Division of Diabetes, Endocrinology and Metabolism, Diabetes and Endocrinology Research Center, and Department of Medicine, Baylor College of Medicine, Houston, TX;
Division of Diabetes, Endocrinology and Metabolism, Diabetes and Endocrinology Research Center, and Department of Medicine, Baylor College of Medicine, Houston, TX;
Division of Diabetes, Endocrinology and Metabolism, Diabetes and Endocrinology Research Center, and Department of Medicine, Baylor College of Medicine, Houston, TX;
Division of Diabetes, Endocrinology and Metabolism, Diabetes and Endocrinology Research Center, and Department of Medicine, Baylor College of Medicine, Houston, TX,Division of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX;
Division of Diabetes, Endocrinology and Metabolism, Diabetes and Endocrinology Research Center, and Department of Medicine, Baylor College of Medicine, Houston, TX,Division of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX;
Division of Diabetes, Endocrinology and Metabolism, Diabetes and Endocrinology Research Center, and Department of Medicine, Baylor College of Medicine, Houston, TX,Division of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX;
机译:抑制胰岛素抵抗并恢复胰岛功能可抑制VEGFR-2逆转NOD小鼠的1型糖尿病。
机译:抗TCRβMAb与神经源性3基因治疗的联合逆转,在雌性Nod小鼠中建立了近1型糖尿病
机译:联合疗法可逆转已建立1型糖尿病的NOD小鼠的高血糖症
机译:基于生物材料的微粒疫苗可逆转NOD小鼠的1型糖尿病
机译:GM-CSF在诱导NOD小鼠对1型糖尿病的耐受性中的作用。
机译:勘误表。 PD-L1驱动的耐受性可保护Neurogenin3诱导的胰岛新生以逆转NOD小鼠中已建立的1型糖尿病。糖尿病2015; 64:529-540
机译:错误。 PD-L1驱动耐受性保护神经源性3诱导的胰岛新发生,以在NOD小鼠中逆转建立的1型糖尿病。 2015年糖尿病; 64:529-540
机译:来自年轻NOD小鼠的双阴性(CD3 + 4-8-)TCRalphaBeta脾细胞提供针对1型糖尿病的长期保护